GC
GTHX

Guggenheim Capital’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Guggenheim Capital’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,436
Closed -$79K – 2158
2022
Q1 		$79K Buy
10,436
+133
+1% +$1.26K ﹤0.01% 2103
2021
Q4 		$106K Buy
+10,303
New +$131K ﹤0.01% 2092

Other funds holding GTHX

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Guggenheim Capital's GTHX Position: Q2 2022 in Review

Guggenheim Capital sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2022, closing a stake of 10,436 shares — an estimated $79K sold.

Guggenheim Capital first reported a position in GTHX in Q4 2021 and held it in 2 quarters. The position peaked at $106K in Q4 2021. 98 funds tracked by Wall St. Rank hold GTHX as of Q2 2022.

  • Guggenheim Capital reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Guggenheim Capital sold 10,436 G1 Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $79K.
  • Guggenheim Capital first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • Guggenheim Capital's G1 Therapeutics, Inc. Common Stock position peaked at $106K in Q4 2021.
  • 98 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Guggenheim Capital's 13F filing for Q2 2022, filed 15 Aug 2022.